Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Top Pick Healthcare Technology Co. Trading at Deep Discount
Source: Rob Goff  (7/19/23)
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report. More >

Healthcare Tech Firm Sells Noncore Assets for $6M
Source: Rob Goff  (7/10/23)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report. More >

Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >

Co. Addresses Opioid Crisis Through Novel Platforms
Source: Boobalan Pachaiyappan  (7/7/23)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. More >

Up to 10,000 Patients To Join Telehealth Co.s Platform in Mexico
Source: Streetwise Reports  (7/6/23)
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June. More >

New Psoriasis Drug Shown More Effective Than On-Market One
Source: Julian Harrison   (7/6/23)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. More >

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says
Source: Stefan Quenneville  (7/5/23)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction. More >

Biotech Co. Remains Opportunity for Those With High Risk Tolerance
Source: Stefan Quenneville  (6/30/23)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note. More >

Q3: Chen Is Still Bullish on This Precious Metal
Source: Streetwise Reports  (6/29/23)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. More >

Telehealth Co. Expands to More Patients, Picks Up Coverage
Source: Streetwise Reports  (6/26/23)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention. More >

New Drug for Bone Growth Disorder Improves Height Velocity
Source: Dr. Thomas Shrader  (6/21/23)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

777% Gain Implied in Analyst's Target Price on Biopharma Co.
Source: Dr. Yi Chen  (6/14/23)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. More >

Telehealth Co. Expands With Six New Contracts in Three States
Source: Streetwise Reports  (6/13/23)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said. More >

Court Grants Firm Protection From Creditors
Source: Andrew Semple  (6/12/23)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report. More >

Biotech Co. To Exit Health Care Services
Source: Streetwise Reports  (6/12/23)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. More >

Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: Ed Arce  (6/9/23)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. More >

Medical Device Co. Completes Merger in Q1/23
Source: Jeffrey Cohen  (6/8/23)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report. More >

Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23
Source: Rob Goff  (6/5/23)
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report. More >

FDA Approval, Private Placement Funding Buoy Biotech Firm
Source: Streetwise Reports  (6/5/23)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement. More >

Telehealth Co. Notches First Profitable Quarter
Source: Streetwise Reports  (6/2/23)
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022. More >

Analyst Says Pharma Co. 'Meaningfully Undervalued'
Source: Stefan Quennevill  (6/1/23)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note. More >

U.S. Firm's Earnings To Remain Robust Through 2023
Source: Andrew Semple   (5/25/23)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report. More >

Animal Feed Company Evaluating Strategic Alternatives
Source: Streetwise Reports  (5/23/23)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. More >